Journal: Nature Communications

Article Title: Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

doi: 10.1038/s41467-019-12998-6

Figure Lengend Snippet: Therapeutic efficacy of rMVA-CD40L in unrelated, large, established tumor models. a Experimental layout: briefly, C57BL/6 ( b – e ) or Balb/c mice ( f – i ) received either B16.OVA ( b , c ), MC38.WT ( d , e ), CT26.WT ( f , g ) or CT26.HER2 ( h , i ) cells subcutaneously in the flank. Seven to 14 days later, when tumors were above 60 mm 3 , mice were immunized intravenously either with PBS or with 5 × 10 7 TCID 50 of the mentioned rMVA viruses. b , c B16.OVA; b tumor size follow-up ( n = 5 mice/group) and c overall survival ( n = 10 mice/group) of mice injected either with PBS, MVA-OVA, or MVA-OVA-CD40L; d , e MC38.WT tumor-bearing mice were grouped 18 days after tumor cell inoculation, when tumors were above 90 mm 3 ; d tumor size follow-up ( n = 10 mice/group) and e overall survival ( n = 10 mice/group) of mice injected either with PBS, MVA-TAA, or MVA-TAA-CD40L until day 60 after treatment; f , g CT26.WT; f tumor size follow-up ( n = 5 mice/group), and g overall survival ( n = 5 mice/group) of mice injected either with PBS, MVA-TAA, or MVA-TAA-CD40L; h , i CT26.HER2; h tumor size follow-up ( n = 6 mice/group), and i overall survival ( n = 6 mice/group) of mice injected either with PBS or MVA-HER2-CD40L. b , d , f , and h Data are expressed as mean ± SEM. Panel b is representative of at least two independent experiments. Panel c represents overall survival of two merged independent experiments. The antitumor efficacy of MVA-HER2-CD40L in h and i has been tested in the CT26.HER2 tumor model in at least two independent experiments. One-way ANOVA at day 20 after tumor inoculation was performed on b , d , f , and h . Log-rank test on mouse survival was performed for c , e , g , and i . * p < 0.05; ** p < 0.01; *** p < 0.005

Article Snippet: For anti-HER2 experiments, 5 µg anti-HER2-Trastuzumab-hIgG1 or hIgG1 (Invivogen) were injected i.p. at days −2, 1, and 4 after immunization

Techniques: Injection

Journal: Nature Communications

Article Title: Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

doi: 10.1038/s41467-019-12998-6

Figure Lengend Snippet: Combination of MVA-CD40L and tumor-targeting antibodies enhances tumor growth control. a – d Enhanced tumor growth control when rMVA-CD40L immunization is combined with tumor-targeting antibodies. a , b B16.OVA tumor-bearing mice received PBS or were immunized with 5 × 10 7 TCID 50 of rMVA-CD40L (Day 0). Mice received 200 µg of either IgG2a or anti-TRP-1 antibody i.p. at days −2, 2, 6, and 10. a Tumor size follow-up ( n = 5 mice/group) and b overall survival. c , d Balb/c mice bearing 85–100 mm 3 CT26.HER2 received PBS or were immunized with 5 × 10 7 TCID 50 of MVA-HER2-CD40L (Day 0). Mice received 5 µg of either IgG1 or anti-HER2 antibody i.p. at days –2, 1, and 4. c Tumor size follow-up ( n = 5 mice/group) and d overall survival. Data in a and c are expressed as mean ± SEM, representative of at least two independent experiments. One-way ANOVA was performed on a . Log-rank test on mouse survival was performed for b . * p < 0.05; ** p < 0.01; *** p < 0.005

Article Snippet: For anti-HER2 experiments, 5 µg anti-HER2-Trastuzumab-hIgG1 or hIgG1 (Invivogen) were injected i.p. at days −2, 1, and 4 after immunization

Techniques:

Journal: Nature Communications

Article Title: Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering

doi: 10.1038/s41467-023-42619-2

Figure Lengend Snippet: a – g In vitro ADCC assay. Three human ovarian cancer cell lines (OVCAR3-FG, OVCAR8-FG, and SKOV3-FG) and four effector cells (Vδ2T, MCAR-Vδ2T, MCAR15-Vδ2T, and MCAR-T as a benchmark control) were included in the study. The same CD16 Hi donor PBMCs were used to generate all 4 types of effector cells. a Experimental design. Data were collected at 24 h after co-culture. Anti-HER2 Ab: monoclonal antibody trastuzumab. b FACS detection of HER2 expression on the indicated tumor cell lines. c Killing of OVCAR3-FG tumor cells by Vδ2T cells in the presence of titrated amounts of either isotype control or anti-HER2 Ab ( n = 3). Tumor cell killing data of ( d ) OVCAR3-FG, ( e ) OVCAR8-FG, and ( f ) SKOV3-FG in the presence or absence of anti-HER2 Ab (anti-HER2 Ab concentration = 0.1 μg/mL; E:T ratio = 0.5:1; n = 3). g ELISA measurements of IFN-γ production at 24 h in the presence or absence of anti-HER2 Ab (anti-HER2 Ab concentration = 0.1 μg/mL; E:T ratio = 1:1; n = 3). h , i In vitro repeated tumor cell challenge assay studying ADCC. h Experimental design. Effector cells were mixed with tumor cells and rechallenged every 3 days. Tumor cell killing data was measured at 24 h post co-culture with or without the addition of anti-HER2 antibody (anti-HER2 Ab concentration = 0.1 μg/mL; E:T ratio = 2:1; n = 3). i KO OVCAR3-FG tumor cell killing data collected over time. Representative of 3 experiments. Data are presented as the mean ± SEM. ns, not significant; ** p < 0.01; *** p < 0.001; **** p < 0.0001 by Student’s t test ( c ) or by one-way ANOVA ( d – g ). Sour c e data and exact p values are provided as a Source Data file.

Article Snippet: InVivo SIM anti-human HER2 (Trastuzumab Biosimilar, Cat. SIM0005) was purchased from BioXCell.

Techniques: In Vitro, ADCC Assay, Co-Culture Assay, Expressing, Concentration Assay, Enzyme-linked Immunosorbent Assay

Journal: Sensors & Diagnostics

Article Title: Therapeutic drug monitoring of immunotherapies with novel Affimer–NanoBiT sensor construct

doi: 10.1039/d3sd00126a

Figure Lengend Snippet: K D values calculated from evaluation of Langmuir model fits of SPR curves (Fig. S1†). All anti-idiotypic Affimer proteins have nM affinity for their respective TmAb analytes and are within ∼12-fold of one another. K D values are presented as a mean of three replicates ± SEM. (Aff–Ipi – ipilimumab n = 2)

Article Snippet: Biosimilars of each of the target mAbs were purchased from InvivoGen; rituximab (anti-hCD20-hIgG4 S228P), adalimumab (anti-hTNF-α-hIgG1), trastuzumab (anti-HER2-hIgG4 S228P) and ipilimumab (anti-hCTLA4-hIgG1).

Techniques:

Journal: Sensors & Diagnostics

Article Title: Therapeutic drug monitoring of immunotherapies with novel Affimer–NanoBiT sensor construct

doi: 10.1039/d3sd00126a

Figure Lengend Snippet: Sensitivity (LoD), accuracy (% recovery), and precision (% CV) of TmAb NanoBiT assays, as determined from raw bioluminescence ( Fig. 4A , S5A and C†), or fold gain data ( Fig. 4B , S5B and D†), to define a quantifiable range

Article Snippet: Biosimilars of each of the target mAbs were purchased from InvivoGen; rituximab (anti-hCD20-hIgG4 S228P), adalimumab (anti-hTNF-α-hIgG1), trastuzumab (anti-HER2-hIgG4 S228P) and ipilimumab (anti-hCTLA4-hIgG1).

Techniques: Intra Assay, Inter Assay